BTA test

BTA test

Bladder tumour antigen test. A qualitative, point-of-care test that identifies a human complement factor H-related protein, which is produced by several human bladder cell lines but not by non-malignant epithelial cell lines. It has a claimed sensitivity comparable to that of cytology for high-grade tumours and claimed to be better than cytology for low-grade tumours.
References in periodicals archive ?
17] To understand the nuances of the BTA test and the urine cytology test in diagnosis, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine results.
Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis
A significant interaction was observed between exercise and medication use based on results of the BTA test and the Digit Span Forward and Backward Task.
Some cognitive function in Parkinson's improves with exercise
Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Complement factor H as a marker for detection of bladder cancer
The most significant improvement was experienced by a woman who was 29 years of age chronologically, whose first BTA test showed her to be 43 biological years of age, and whose second BTA test after consumption of the tea showed her to be 27 biological years of age," says Dr.
Study Shows 1890s Indian Tea Can Reverse Biological Aging Process
Because original BTA test sensitivity (approximately 40%) was no better than that of cytology, several assay modifications were introduced, including the BTA stat and BTA TRAK.
BLADDER CANCER MARKERS: Current availability and the future standard of care
He has also served as President and CEO of Bard Diagnostics (formerly Bainbridge Sciences), a pioneering cancer diagnostics company that developed and launched the BTA test, the first diagnostic test for bladder cancer approved by the U.
LifeSpex Appoints New CEO; Healthcare Executive Will Lead Approval and Launch of CerviScan
3,4] A number of novel immunoassays for cancer-associated proteins in voided urine have been investigated as diagnostic tool to replace cytology, including BTA test, BTA Stat test, NMP22 and Immunocyt.
A pilot study of urinary microRNA as a biomarker for urothelial cancer
After collecting samples of a patient's blood, urine and saliva, the health care practitioner performs a 10-minute BTA test resulting in a complex evaluation of the patient's cellular health.
Magellan Unveils New Health Evaluation Tool
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder.
Current concepts in biomarker technology for bladder cancers
urinary cytology and the BTA test, with the advantage of being
Matritech's NMP22(R) Test Kit For Bladder Cancer Found Superior to Other Tests According to Study by Institute of Urology in Milan, Italy
The new, rapid BTA stat test is even simpler to perform and improves upon the original Bard BTA Test.
Revolutionary new test for bladder cancer receives FDA clearance
Bard, will market, sell and distribute the BTA Test to the Japanese market.
BTA(R) Test Receives Japanese Approval
Medical browser ?
Full browser ?